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Background: Claudin-1 is a membrane protein of tight junctions, and is associated with the development of
various cancers. However, the significance of claudin-1 expression in cancer cells is not well understood. Here, we
showed for the first time the anti-apoptotic effect of claudin-1 in human breast cancer MCF-7 cells.
Methods: Human breast cancer MCF-7 and T47 D cells were treated with or without tamoxifen, siRNA against
claudin-1, or tamoxifen and claudin-1 siRNA. The samples were analyzed by RT-PCR, Western blotting or
immunofluorescent staining.
Results: The expression of claudin-1 was upregulated in tamoxifen-treated MCF-7 cells, whereas the expression of
claudin-1 was not altered in tamoxifen-treated T47 D cells. Knockdown of claudin-1 by siRNA increased the amount
of poly (ADP-ribose) polymerase (PARP) regardless of tamoxifen treatment in MCF-7 cells, but not T47 D cells. In
the cell membranes of the MCF-7 cells, tamoxifen treatment increased the amount of claudin-1, but decreased the
amount of b-catenin. Claudin-1 siRNA increased the amount of E-cadherin in the cytoplasm of the MCF-7 cells as
well as the amount of b-catenin in their cell membranes.
Conclusion: These results indicate that claudin-1 has anti-apoptotic effects, and is involved in the regulation of the
expression and subcellular localization of b-catenin and E-cadherin in MCF-7, but not T47 D cells.
Background
Breast cancer is the second most common cause of
female mortality in United States. The breast cancer
incidence and mortality rates were about 190,000 and
40,000, respectively, in 2009 [1]. The majority of breast
cancers are sporadic, and most risk factors for the dis-
ease are related to estrogen exposure. This suggests that
insufficient apoptosis in cancer cells is involved in their
survival as insuffcient apoptosis leads to the develop-
ment of chemotherapy resistance and carcinogenesis [2].
Tamoxifen is one of most widely used anti-estrogen
drugs for the treatment of human breast cancer [3].
Tamoxifen treatment leads to a rapid decrease in num-
ber of S-phase cells, an accumulation of cells in the G1-
fraction [4], and the induction of apoptosis in vivo and
vitro [5-7]. Tamoxifen induces apoptosis through several
distinct pathways including a mitochondria-dependent
pathway, the induction of c-Myc, the activation of mem-
bers of the mitogen-activated protein kinases (MAPK)
family, and the upregulation of p53 [7-11]. However, the
detailed molecular mechanisms by which tamoxifen
induces apoptosis are not well understood.
Tight junctions and adherens junctions proteins,
including claudins, E-cadherin, b-catenin, and ZOs pro-
teins, are responsible for the maintenance of epithelial
cell-cell adhesion and defining cell polarity, and are also
involved in cell signaling events [12]. Changes in claudin
expression are also involved in invasion, metastasis, and
colony formation in various cancer cells [13-15]. In a
previous study, the mRNA expression of claudin-1 was
decreased in the tumor group compared with the con-
trol (normal) group in breast cancer tissues [16].
Decreased expression of claudin-1 was also correlated
with breast cancer recurrence [17]. However, the rela-
tionship between claudin-1 and chemotherapy is poorly
understood.
In the present study, we investigated the relationship
between claudin-1 and tamoxifen treatment in human
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claudin-1 was upregulated by tamoxifen treatment in
MCF-7 cells. Combination treatment with both claudin-
1 siRNA and tamoxifen significantly increased the
amount of cleaved PARP. Knockdown of claudin-1
affected the expression and subcellular localization of b-
catenin and E-cadherin in MCF-7 cells. Our results sug-
gest that claudin-1 has an anti-apoptotic effect, involving
the regulation of b-catenin and E-cadherin, in MCF-7
cells.
Methods
Cell culture and treatment
MCF-7 and T47 D cells were obtained from the Ameri-
can Type Culture Collection (ATCC, Manassas, VA,
USA). These cells were cultured in Dulbecco’sM o d i f i e d
Eagle’s Medium-high glucose (Sigma Chemical Co., St.
Louis, MO, USA) supplemented with 10% fetal bovine
serum at 37°C in a humidified atmosphere of 95% air
and 5% CO2. When the MCF-7 cells were treated with
40 μM of tamoxifen (Sigma) for 20 h, apoptotic reac-
tions were detected as described below. However, the
incubation with 40 μM of tamoxifen for more than 24 h
resulted in the severe toxicity to cells, and more than
90% of cells were detached from the plates (data not
shown). Therefore, we treated the cells with 40 μMo f
tamoxifen for 20 h in the follow experiments. In addi-
tion, we treated MCF-7 cells with 1, 10 or 20 μMo f
tamoxifen for 48 h in some experiments to observe the
longer effects.
Reverse transcription-polymerase chain reaction (RT-PCR)
and real-time PCR
Total RNA was isolated using an RNeasy RNA isolation
kit (QIAGEN, Hilden, Germany). First-strand cDNA was
synthesized from 1 μgo ft o t a lR N Au s i n gR e v e r T r aA c e
(TOYOBO, Osaka, Japan). RT-PCR was performed using
an aliquot of first-strand cDNA as a template under stan-
dard conditions with Taq DNA polymerase (QIAGEN).
The primers were designed to perform optimal RT-PCR
by DNASIS software, and the primers used were as fol-
lows: claudin-1-F: 5’-CAGCTGTTGGGCTTCATTCTC-
3’, claudin-1-R: 5’-ATCACTCCCAGGAGGATGCC-3’;
claudin 4-F: 5’-ATGGCCTCCATGGGGCTACA-3’, clau-
din 4-R: 5’-AGCGAGTCGTACACCTTGCA-3’;E - c a d -
herin-F: 5’-ACATTGTCACCTCGCAGAC-3’, E-cadherin-
R: 5’-GCGGATTGTAGAAGTCTTGG-3’; GAPDH-F: 5’-
CCACCCATGGCAAATTCCATGGCA-3’,G A P D H - R :5 ’-
AGACCACCTGGTGCTCAGTGTAGC-3’. The amplified
products of claudin-1, claudin-4, E-cadherin, and GAPDH
were 277 bp, 208 bp, 336 bp, and 696 bp, in length,
respectively. The cDNA for claudin-1, claudin-4, E-cad-
herin, and GAPDH were amplified for up to 25 cycles.
The PCR products were separated on 1.5% (w/v) agarose
gels.
The real-time PCR was carried out using SYBER Green
Master Mix (Applied Biosystems, Tokyo, Japan). The pri-
mers used as follows: claudin-1-F: 5’-AGATGAG-
GATGGCTGTCATTGG -3’,c l a u d i n - 1 - R :5 ’-CATGCT
GTGGCAGCTAAAATAGC-3’; E-cadherin-F: 5’-ACAT
TGTCACCTCGCAGAC-3’, E-cadherin-R: 5’-GCGGAT
TGTAGAAGTCTTGG-3’;1 8Sr R N A - F :5 ’-GTAACC
CGTTGAACCCCATT-3’,1 8Sr R N A - R :5 ’-CCATC-
CAATCGGTAGTAGCG-3’. The amplified products of
claudin-1, E-cadherin, and 18 S rRNA were 72 bp, 336 bp,
and 150 bp, in length, respectively.
Short interference RNA (siRNA)
Short interference RNA (siRNA) against claudin-1 were
synthesized by QIAGEN. The sequences for the sense and
anti-sense claudin-1 siRNA were 5’-r (GCAUGGUAUGG-
CAAUAGAA) d (TT) -3’ and 5’-r (UUCUAUUGC-
CAUACCAUGC) d (TG) -3’, respectively. We also used
another siRNA against claudin-1 (claudin-1 siRNA2). The
sequences for the sense and anti-sense claudin-1 siRNA2
were 5’-r (CGAAAUUGUUACAAUAGAA) d (TT)-3’ and
5’-r (UUCUAUUGUAACAAUUUCG) d (TT)-3’.T h e
negative control (scrambled) siRNA sequences were 5’-r
(UUCUCCGAACGUGUCACGU) d (TT)-3’ and 5’-r
(ACGUGACACGUUCGGAGAA) d (TT)-3’.F o rt h e
siRNA transfection experiments, MCF-7 and T47 D cells
were seeded at 5 × 10
4 cells per 35-mm well. Twenty-four
h later, the siRNA were transfected into the cells using the
Lipofectamine RNA iMAX reagent (Invitrogen, Carlsbad,
CA, USA). After transfection, the cells were incubated for
48 h and subjected to various analyses.
Western Blotting
The cells transfected with siRNA were lysed using M-
PER lysis buffer (PIERCE, Rockford, IL, USA). Protein
concentrations were determined using the bicinchoninic
acid (BCA) assay. The obtained lysates (10 μgp r o t e i n )
were subjected to SDS-PAGE, and the acquired proteins
were transferred to PVDF membranes (Immobilion P,
Millipore, Tokyo, Japan). The membranes were then
incubated with antibodies specific for claudin-1
(1:10,000), claudin-4 (1:20,000), and claudin-7 (1:2,000),
which were purchased from Invitrogen; E-cadherin
(1:1,000), which was purchased from Takara, Shiga,
Japan; b-catenin (1:30,000), Bcl-2 (1:2,000), and p21
(1:1,000), which were purchased from EPITOMICS, CA,
USA; cyclin D1 (1:1,000), which was purchased from
Merck, Darmstadt, Germany; PARP (1:1,000) and
cleaved caspase-8 (1:10,000), which were purchased
from Cell Signaling Technology, Inc Danvers, MA, USA;
Bax (1:1,000), which was purchased from Santa Cruz,
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Abcam, Cambridge, UK; and actin (1:30,000) (Sigma),
followed by treatment with horseradish peroxidase-con-
jugated secondary antibody (IBL, Gunma, Japan). Can
Get Signal Immunoreaction Enhancer Solution 1
(TOYOBO) was used to dilute the primary antibody.
The ECL, ECL-plus, or ECL-advance Western Blotting
Detection System (Amersham, Uppsala, Sweden) was
used for detection. The intensity of the bands was quan-
tified by using the National Institute of Health Image
computer program. The signal intensities were compen-
sated by actin as internal controls.
Immunofluorescent staining
MCF-7 and T47 D cells were seeded on a 4-chamber
slide glass and incubated overnight. The cells were then
washed with phosphate-buffered saline (PBS) and fixed
with ice-chilled methanol for 30 min, before being per-
meabilized with 0.2% Triton-X-100 in PBS for 30 min.
The permeabilized cells were then washed in PBS twice
and treated with 5% normal horse serum in PBS for 30
min (to minimize the non-specific adsorption of antibo-
dies), before being incubated with anti-claudin-1 (1:200),
anti-b-catenin (1:300), or anti-E-cadherin (1:300) antibo-
dies at 4°C overnight. The cells were then incubated for
1 h with goat anti-rabbit IgG antibody conjugated to
Alexa 488 dye (Molecular Probes, Inc, Tokyo, Japan),
while nuclear staining was performed using 4’,6 - d i a m i -
dino-2-phenylindole (DAPI) or Hoechst 33258. Hoechst
33258 staining was used to examine nuclear condensa-
tion. The cells were visualized using confocal laser scan-
ning microscopy (Zeiss, LSM7 1 0 ,W e t z l a r ,G e r m a n y ) ,
and the number of cells that were intensely stained with
Hoechst 33258 was counted.
Results
Tamoxifen treatment induces apoptosis and upregulates
the expression of claudin-1 in MCF-7 cells
We investigated the endogenous expression of claudin-1
in two breast cancer cell lines by Western blotting. The
endogenous protein expression of claudin-1 was weak in
MCF-7 cells, whereas it was abundantly expressed in
T47 D cells (Figure 1A and 1B). In addition, E-cadherin
was abundantly expressed in both MCF-7 and T47 D
cells. Next, we examined the relationship between
tamoxifen and claudin-1. We examined how the protein
expression of claudin-1 was affected by tamoxifen treat-
ment. MCF-7 and T47 D cells were treated with various
concentrations of tamoxifen for 20 h. Cell lysates were
prepared from cells and subjected to Western blot ana-
lysis. The protein expression of claudin-1 was slightly
increased by treatment with 20 μM tamoxifen in MCF-7
cells, and the cells treated with 30 or 40 μMo ft a m o x i -
fen treatment showed clear increases in their claudin-1
protein levels. Twenty, 30, or 40 μM of tamoxifen treat-
ment also increased the amounts of cleaved PARP and
caspase-8 in the MCF-7 cells, but decreased their
expression of b-catenin. The protein expression of
E-cadherin was decreased in MCF-7 cells after treatment
with 30 or 40 μM of tamoxifen. We also examined
whether the longer exposure to tamoxifen affects the
expression of claudin-1 in MCF-7 cells. The expression
of claudin-1 and the amount of cleaved PARP were sig-
nificantly increased in the cells treated with 20 μMo f
tamoxifen for 48 h (Figure 1C and 1D). In T47 D cells,
the amounts of cleaved PARP and caspase-8 were
increased, whereas the expression of E-cadherin was
decreased after 40 μM of tamoxifen treatment. However,
the protein expression levels of claudin-1, claudin-4,
claudin-7, and b-catenin in T47 D cells were almost
unaffected by tamoxifen treatment. We also examined
whether the expression of claudin-1 mRNA was affected
by tamoxifen treatment. MCF-7 and T47 D cells were
treated with various concentrations of tamoxifen for
20 h, and RNA samples were prepared from the cells
and subjected to RT-PCR and real-time PCR analyses
for claudin-1, claudin-4, E-cadherin, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), and 18 S rRNA
(Figure 2A and 2B). The mRNA levels of claudin-1 were
significantly increased in MCF-7 cells after treatment
with 30 or 40 μM of tamoxifen, whereas tamoxifen
treatment did not affect the expression of claudin-1 in
T47 D cells. The mRNA expression of E-cadherin was
decreased in both MCF-7 and T47 D cells after treat-
ment with 40 μM of tamoxifen. On the other hand,
tamoxifen treatment did not affect the expression of
claudin-4 in MCF-7 or T47 D cells.
Nuclear condensation is one of the features of apopto-
sis. Using immunofluorescent staining, we examined
whether tamoxifen treatment induces nuclear condensa-
tion. MCF-7 and T47 D cells were treated with tamoxi-
fen, fixed, and then stained with Hoechst 33258.
Nuclear condensation was increased about 9 or 5-fold in
MCF-7 or T47 D cells, respectively, treated with 40 μM
of tamoxifen compared with that in the untreated-con-
trol cells (Figure 3A and 3B).
Claudin-1 has anti-apoptotic effects under tamoxifen
treatment in MCF-7 cells
To understand the mechanism of the upregulation of
claudin-1 expression by tamoxifen treatment, we exam-
ined whether the transfection of claudin-1 siRNA
affected the expression of factors related to apoptosis.
MCF-7 cells were transfected with control siRNA or
siRNA against claudin-1. After 48 h of transfection, the
cells were treated with 40 μM of tamoxifen for 20 h.
The cell lysates were then subjected to Western blot
analyses for claudin-1, cleaved PARP, cleaved caspase-8,
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Page 3 of 13Figure 1 The protein levels of claudin-1 were increased in MCF-7 cells treated with tamoxifen. (A) MCF-7 and T47 D cells were treated
with the control treatment (buffer alone: Mock) for 20 h or 20, 30, or 40 μM of tamoxifen for 20 h, cell lysates were prepared and subjected to
Western blot analyses for cleaved PARP, claudin-1, claudin-4, claudin-7, E-cadherin, cleaved caspase-8, and actin. One representative of at least
three independent experiments with similar results is shown. (B) The intensity of the bands for cleaved PARP, claudin-1 and E-cadherin in
untreated and tamoxifen (40 μM) - treated cells were quantified. (C) MCF-7 cells were treated with or without 1, 10 or 20 μM of tamoxifen for
48 h, cell lysates were prepared and subjected to Western blot analyses for cleaved PARP, claudin-1 and actin. One representative of at least
three independent experiments with similar results is shown. (D) The intensity of the bands for cleaved PARP and claudin-1 in untreated and
tamoxifen (40 μM) - treated cells were quantified.
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Page 4 of 13Figure 2 The mRNA levels of claudin-1 were increased in MCF-7 cells treated with tamoxifen. (A) After the MCF-7 and T47 D cells had
been treated with various concentrations of tamoxifen for 20 h and subjected to RT-PCR analyses. One representative of at least three
independent experiments with similar results is shown. (B) MCF-7 and T47 D cells were treated with or without 40 μM of tamoxifen for 20 h,
and subjected to real-time PCR analyses for claudin-1 and E-cadherin. Each value represents the mean + SE (bars) of three independent
experiments *p < 0.05, according to the t-test.
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Page 5 of 13E-cadherin, b-catenin, Bax, Bcl-2, cyclinD1, p53, p21,
and actin (Figure 4A and 4B). Claudin-1 knockdown by
siRNA significantly reduced the expression of claudin-1
with or without tamoxifen treatment, and the transfec-
tion of claudin-1 siRNA increased the amounts of
cleaved PARP and caspase-8 with or without tamoxifen
treatment. The expression of E-cadherin was upregu-
lated by claudin-1 knockdown without tamoxifen treat-
ment, while the expression of E-cadherin in the
presence of claudin-1 siRNA and tamoxifen treatment
was slightly increased. On the other hand, the expres-
sion of cyclinD1 was downregulated by claudin-1
Figure 3 Nuclear condensation was detected by tamoxifen treatment both in MCF-7 and T47 D cells. (A) MCF-7 and T47 D cells were
seeded in a 4-chamber slide glass and incubated overnight. The cells were treated with or without 40 μM of tamoxifen for 20 h, fixed, and
stained with Hoechst 33258. The arrows show nuclear condensation. (B) Percentage of cells intensely fragmented and condensed in nuclei with
Hoechst 33258 were counted as positive cells. About 100 total cells were counted in individual ten random microscopic fields at ×40
magnification. Each value represents the mean + SE (bars) of two independent experiments *p < 0.05, according to the t-test.
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Page 6 of 13Figure 4 Anti-apoptotic effect of claudin-1 induced by tamoxifen in MCF-7 cells. (A) MCF-7 cells were transfected with control siRNA or
siRNAs against claudin- 1 (left: claudin-1 siRNA, right: claudin-1 siRNA2) and incubated for 48 h, before being treated with or without 40 μMo f
tamoxifen and then incubated for a further 20 h. Cell lysates were prepared from the cells and subjected to Western blot analyses for claudin-1,
cleaved PARP, cleaved caspase-8, E-cadherin, b-cadherin, Bax, Bcl-2, cyclinD1, p53, p21, and actin. One representative of at least three
independent experiments with similar results is shown. (B) The intensity of the bands for claudin-1, cleaved PARP, E-cadherin, b-cadherin and
cyclinD1 in control siRNA and claudin-1 siRNA - treated cells with or without tamoxifen (40 μM) for 20 h were quantified.
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Page 7 of 13knockdown with or without tamoxifen treatment,
whereas tamoxifen treatment did not affect the expres-
sion of cyclinD1. The expression of b-catenin was upre-
gulated by claudin-1 knockdown in the absence of
tamoxifen treatment, but combination treatment invol-
ving claudin-1 siRNA and tamoxifen had little effect the
expression of b-catenin. The expression levels of Bax,
Bcl-2, p53, p21, and actin were not affected by claudin-1
knockdown, tamoxifen treatment or combination treat-
ment involving claudin-1 siRNA and tamoxifen.
As nuclear condensation was induced in the cells trea-
ted with tamoxifen (Figure 3), we examined whether
claudin-1 siRNA treatment had similar effects. Nuclear
condensation was increased about 7-fold in the MCF-7
cells treated with claudin-1 siRNA as well as the control
siRNA and tamoxifen-treated cells compared with that
in the control (only control siRNA treatment) cells (Fig-
ure 5). Combination treatment involving claudin-1
siRNA and tamoxifen increased nuclear condensation
about 16-fold compared with that in the control cells.
Next, we examined whether claudin-1 knockdown by
siRNA affected the amount of cleaved PARP in T47 D
cells. The amount of cleaved PARP was upregulated by
tamoxifen treatment, but it was little affected by claudin-
1 siRNA treatment or combination treatment involving
claudin-1 siRNA and tamoxifen (Figure 6A and 6B).
Changes in the subcellular localization of E-cadherin and
b-catenin in MCF-7 cells treated with claudin-1 siRNA or
tamoxifen
We investigated whether the subcellular localization of
E-cadherin and b-catenin was affected by claudin-1
siRNA or tamoxifen treatment using immunofluorescent
staining. As shown in Figure 7A and 8A, tamoxifen treat-
ment increased the amount of claudin-1 in the cell mem-
branes of MCF-7 cells, while tamoxifen treatment did
not affect the amount of claudin-1 in T47 D cells.
Tamoxifen treatment decreased the amounts of E-cad-
herin in the cell membranes of MCF-7 and T47 D cells,
while it increased the amount of E-cadherin in the cyto-
plasm of MCF-7, but not T47 D, cells. On the other
hand, tamoxifen treatment decreased the amount of
b-catenin in the cell membranes of MCF-7 cells, but
increased it in the cytoplasm. The amount of E-cadherin
in the cell membrane was decreased in MCF-7 cells
treated with claudin-1 siRNA, while the amount of
E-cadherin in the cytoplasm was increased (Figure 7B).
Knockdown of claudin-1 also increased the amount of
b-catenin in the cell membranes of MCF-7 cells. In T47
D cells, claudin-1 siRNA treatment did not affect the
amount of E-cadherin or b-catenin in the cell membrane
or cytoplasm (Figure 8B). These data demonstrated that
claudin-1 has anti-apoptotic effects during tamoxifen
treatment, which involve changes in the subcellular
localization of claudin-1, E-cadherin, and b-catenin in
MCF-7 cells.
Discussion
In this study, we focused on the functions of claudin-1
in human breast cancer cells. Claudins are generally
located in the cell membrane and mainly contribute to
cell-cell adhesion [18,19]. It was confirmed that claudin-
1 is localized to the cell membrane in T47 D cells. How-
ever, little claudin-1 was localized to the cell membrane
in MCF-7 cells. Tamoxifen treatment increased claudin-
1 protein expression as well as its membrane localiza-
tion in MCF-7 cells, whereas tamoxifen treatment did
not affect the expression or subcellular localization of
claudin-1 in T47 D cells. Thus, the function of claudin-
1 may differ among different cell types. It has been
reported that MCF-7 cells have wild type p53 but lack
caspase-3. On the other hand, T47 D cells express cas-
pase-3 but p53 is mutated [20,21]. They showed that the
sensitivity of these cells against anti-cancer drugs such
as staurosporine and Triphala are different. The differ-
ential expression of claudin-1 may be also related to dif-
ferences in phenotype of these two cell lines.
Recent studies have shown the relationship between
claudin expression and cellular resistance in tumors
[22,23]. The elevated claudin-1 expression induced by
5-fluorouracil (5-FU) or TNF-a treatment is associated
with the regulation of apoptosis in nasopharyngeal carci-
noma and pancreatic cancer cells, although these cells
low levels of protein expression and claudin-1 localiza-
tion in the membrane were also observed [23,24]. In
addition, knockdown of claudin-6 induces cellular
Figure 5 Nuclear condensation was increased in claudin-1 siRNA
treatment of MCF-7. MCF-7 cells were treated as above, and then
stained with Hoechst 33258. Percentage of cells intensely fragmented
and condensed in nuclei with Hoechst 33258 were counted as
previously described, and each value represents the mean + SE (bars)
of two independent experiments *p < 0.05, according to the t-test.
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Page 8 of 13resistance to apoptosis in MCF-7 cells [22]. These
observations and our findings suggest that the upregula-
tion of claudin-1 by apoptosis-inducers contributes to
cellular resistance to apoptosis when claudin-1 protein
is expressed at low levels and mislocalized to the cell
membrane. However, it is unclear how claudin-1 is
regulated by apoptosis inducers. We found that tamoxi-
fen treatment increased the expression of claudin-1
mRNA and proteins related to apoptosis in MCF-7 cells.
We speculate that tamoxifen treatment regulates the
transcription of claudin-1. Further studies are needed to
interpret whether tamoxifen treatment regulates clau-
din-1 expression.
Next, we investigated the molecular mechanisms of
the apoptosis induced by claudin-1 knockdown in MCF-
7 cells. Unfortunately, apoptosis-related proteins, such
as Bax, Bcl-2, p53, and p21, were not affected by clau-
din-1 knockdown with or without tamoxifen treatment.
Figure 6 Claudin-1 knockdown has little effects on apoptosis in T47 D cells. (A) T47 D cells were treated with control siRNA or siRNA
against claudin-1 and treated as above. Cell lysates were subjected to Western blot analyses for claudin-1, cleaved PARP, E-cadherin, and actin.
One representative of at least three independent experiments with similar results is shown. (B) The intensity of the bands for claudin-1, cleaved
PARP and E-cadherin in control siRNA and claudin-1 siRNA - treated cells with or without tamoxifen (40 μM) for 20 h were quantified.
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Page 9 of 13Figure 7 Subcellular localization of claudin-1, E-cadherin, and b-catenin in MCF-7 cells after tamoxifen or claudin-1 siRNA treatment.
(A) MCF-7 cells were treated with or without 40 μM of tamoxifen for 20 h, fixed, incubated with anti-claudin-1, E-cadherin or b-catenin antibody,
and visualized using Alexa488-conjugated secondary antibody (Green). The cells were also counterstained with DAPI (Blue) in order to localize
the nucleus. A merged image that is representative of at least two independent experiments with similar results is shown. White dot box for
high magnification were also shown. (B) MCF-7 cells were transfected with siRNA against claudin-1. After 48 h incubation, the cells were fixed,
incubated with anti-E-cadherin or b-catenin antibody, and visualized using Alexa488. One representative merged image is shown.
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Page 10 of 13Figure 8 Subcellular localization of claudin-1, E-cadherin, and b-catenin in T47 D cells after tamoxifen or claudin-1 siRNA treatment.
(A) T47 D cells were treated with or without 40 μM of tamoxifen for 20 h, incubated with anti-claudin-1, E-cadherin, or b-catenin antibody, and
visualized using Alexa488. One representative merged image is shown. (B) T47 D cells were transfected with siRNA against claudin-1. After 48 h
incubation, the cells were fixed, incubated with anti-E-cadherin or b-catenin antibody, and visualized using Alexa488. One representative merged
image is shown.
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lated by claudin-1 knockdown, regardless of tamoxifen
treatment in MCF-7 cells. We speculate that the regula-
tion of apoptosis by claudin-1 knockdown may be
related to pathways other than the p21, p53, and mito-
chondrial-pathways. Lee et al. showed that claudin-1 has
anti-apoptotic effects under 5-FU treatment, but they
could not demonstrate the molecular mechanisms of
claudin-1 induced apoptosis [23].
Interestingly, it has been reported that changes in the
subcellular localization of b-catenin or E-cadherin may
be related to the regulation of apoptosis [25-28].
2-methoxyestradiol induces b-catenin expression in
prostate cancer cells, but blocks b-catenin degradation,
as well as its cytoplasmic or nuclear accumulation,
resulting in cell cycle arrest and apoptosis [29]. There-
fore, we performed immunofluorescent staining to ana-
lyze the changes in the subcellular localization of
b-catenin and E-cadherin induced by claudin-1 knock-
down or tamoxifen treatment. As expected, claudin-1
knockdown affected the subcellular localization of
b-catenin and E-cadherin in MCF-7, but not T47
D cells. Tamoxifen treatment also affected the subcellu-
lar localization of b-catenin and E-cadherin. So, we
speculate that knockdown of claudin-1 upregulates the
p r o t e i ne x p r e s s i o no fb-catenin and changes its subcel-
lular localization in MCF-7 cells and then induces cell
cycle arrest, resulting in apoptosis. However, tamoxifen
treatment downregulates the expression of b-catenin in
MCF-7 cells. According to these results, we suggest that
tamoxifen treatment upregulates the expression of clau-
din-1 and that the upregulation of claudin-1 subse-
quently downregulates the expression of b-catenin.
b-catenin may be one of the downstream factors of
claudin-1 in MCF-7 cells. However, the detailed
mechanism by which claudin-1 regulates the expression
of b-catenin needs to be clarified.
We also examined whether other claudins are affected
by tamoxifen treatment. The expression of claudin-4
and claudin-7 was not affected by tamoxifen treatment
in MCF-7 and T47 D cells as shown in Figure 1A and
2A. Thus, only claudin-1 in claudin’s family would be
specifically affected by tamoxifen treatment, although we
could not elucidate the specific effect of claudin-1 by
tamoxifen treatment.
In the present study, we demonstrated the function of
claudin-1 in human breast cancer MCF-7 cells. Claudin-
1 has anti-apoptotic effects in tamoxifen-treated MCF-7
cells.
Conclusion
We demonstrated the function of claudin-1 in human
breast cancer MCF-7 cells. Our results showed for the
first time that claudin-1 has anti-apoptotic effects in
tamoxifen-treated MCF-7 cells, involving the regulation
of apoptosis-related factors and subcellular localization
of adherens junctions.
Our data would be useful for future studies in order
to establish the mechanisms of apoptosis regulation in
human breast cancer. Further research needs to be clari-
fied the relationship between tight junctions and
apoptosis.
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